New drugs under clinical development in myelofibrosis.
| Drug . | Company . | Phase . | Indication . | Route . | Primary target . |
|---|---|---|---|---|---|
| JAK2 inhibitors | |||||
| INCB01842447 | Incyte | Phase I/II | Myelofibrosis | Oral | JAK2 |
| XLO1945 | Elelixis | Phase I | Myelofibrosis | Oral | JAK2 |
| TG10134841 | TargeGen | Phase I/II | Myelofibrosis | PMF | JAK2 |
| HDAC inhibitor | |||||
| ITF235767 | Italfarmaco | Phase II | Essential thrombocythemia, Polycythemia vera, Myelofibrosis | Oral | HDAC |
| Methyltransferase inhibitor | |||||
| 5-azacitidine58 | Pharmion | Phase II | Myelofibrosis | Subcute | DNA methyltransferase |
| Drugs targeting angiogenesis | |||||
| CC-4047 (Actimid®) | Celgene Corp. | Phase I/II | Myelofibrosis | Oral | angiogenesis |
| Bevacizumab (Avastin®) | Genentech | Phase II | Myelofibrosis | I.V. | VEGF |
| Sunitinib | Pfizer | Phase II | Myelofibrosis | Oral | PDGFR VEGFr, FLT-3, c-KIT |
| Others | |||||
| MK-0457 (VX680) | Merck | Phase I | Relapsed/refractory hematological malignancies, including JAK2617V>F-positive MPD | I.V. | Aurora kinases (A,B,C) |
| CEP-70149 | Cephalon | Phase II | Myelofibrosis | Oral | FTL3 |
| AT9283 | Astex Therapeutics | Phase I/II | Myelofibrosis | I.V. | Aurora kinases |
| GX15-070MS | Gemin X | Phase II | Myelofibrosis | I.V. | Bcl-2 |
| Drug . | Company . | Phase . | Indication . | Route . | Primary target . |
|---|---|---|---|---|---|
| JAK2 inhibitors | |||||
| INCB01842447 | Incyte | Phase I/II | Myelofibrosis | Oral | JAK2 |
| XLO1945 | Elelixis | Phase I | Myelofibrosis | Oral | JAK2 |
| TG10134841 | TargeGen | Phase I/II | Myelofibrosis | PMF | JAK2 |
| HDAC inhibitor | |||||
| ITF235767 | Italfarmaco | Phase II | Essential thrombocythemia, Polycythemia vera, Myelofibrosis | Oral | HDAC |
| Methyltransferase inhibitor | |||||
| 5-azacitidine58 | Pharmion | Phase II | Myelofibrosis | Subcute | DNA methyltransferase |
| Drugs targeting angiogenesis | |||||
| CC-4047 (Actimid®) | Celgene Corp. | Phase I/II | Myelofibrosis | Oral | angiogenesis |
| Bevacizumab (Avastin®) | Genentech | Phase II | Myelofibrosis | I.V. | VEGF |
| Sunitinib | Pfizer | Phase II | Myelofibrosis | Oral | PDGFR VEGFr, FLT-3, c-KIT |
| Others | |||||
| MK-0457 (VX680) | Merck | Phase I | Relapsed/refractory hematological malignancies, including JAK2617V>F-positive MPD | I.V. | Aurora kinases (A,B,C) |
| CEP-70149 | Cephalon | Phase II | Myelofibrosis | Oral | FTL3 |
| AT9283 | Astex Therapeutics | Phase I/II | Myelofibrosis | I.V. | Aurora kinases |
| GX15-070MS | Gemin X | Phase II | Myelofibrosis | I.V. | Bcl-2 |